Boult Wade Tennant
/de

Archive: Bulletins

November 3, 2020

Changes to unregistered designs right after Brexit

Many designers rely on Unregistered Design Rights to protect their products in the UK and the EU. However, designers need to be

Oktober 5, 2020

Trade Marks and design rights after Brexit

This bulletin covers some important changes to trade mark and design rights in the UK that will take place on 1 January

September 30, 2020

High Court confirms that an Artificial Intelligence cannot be named as an inventor

Last year, the UK Intellectual Property Office (UKIPO) rejected two UK patent applications (GB1816909.4 and GB1818161.0) on the grounds of an invalid

September 15, 2020

T0161/18 – Sufficiency and Machine Learning at the EPO

In recent years, the European Patent Office (EPO) has made it eminently clear that European patents may be granted for machine learning

August 28, 2020

Renewal fee increases in Australia

The Australian Patent Office will be changing various official fees for patents, trademarks and designs from 1 October 2020. Notably, patent renewal

August 4, 2020

Apportionment of costs at oral proceedings

Oral Proceedings are a common occurrence during the opposition procedure at the European Patent Office.  Importantly, these proceedings provide the patentee and

Juli 20, 2020

Emson v. Hozelock: Public prior use and a “mere paper proposal”

On 8 July 2020, the Court of Appeal issued its decision in the Emson v. Hozelock case ([2020] EWCA Civ 871). The

Juli 19, 2020

Patentability of simulations – Decision of the Enlarged Board of Appeal for G1/19.

The thorny issue of the patentability (or otherwise) of inventions involving computer simulations at the EPO has been provided with an ending,

Juli 14, 2020

The CJEU Confirms that Copyright Can Cover Products Designed to Achieve a Technical Result

When does a technical product become eligible for copyright protection? This is the question the Court of Justice of the European Union

Juli 3, 2020

Criteria for basing SPCs on functional claims clarified by CJEU in Royalty Pharma

In the latest of a series of judgments concerning the interpretation of Article 3(a) of the SPC Regulation, the Court of Justice